Clinical Trials Logo

Clinical Trial Summary

The purpose and objectives of the study is to establish the feasibility of the simultaneous PET/MR in patients with cardiac sarcoidosis, determine relationships between various imaging biomarkers like extracellular volume (ECV) and standardized uptake values (SUV) from FDG-PET and to evaluate the diagnostic accuracy of the simultaneous method in comparison to the PET/CT and cardiac MRI.


Clinical Trial Description

Patients who meet the inclusion criteria and agree to the study will be recruited from the Kirklin Clinic and UAB hospitals who will be undergoing FDG-PET/CT for cardiac study as part of their standard of care to diagnose cardiac sarcoidosis. MRI and FDG-PET screening questionnaire will be completed. A chart review will be completed to obtain data from patient medical records pertaining to study including age, gender, race, weight, height, vital signs, social and family history, past medical history especially if there is any history of hypertension, diabetes, high cholesterol levels, heart failure or history of lung diseases, lab results including brain natriuretic peptide levels, creatinine, hemoglobin, coagulation parameters, results of stress test/left heart catheterization, prior echocardiography if available. The CMR will be done solely for research purposes. The patient will be in the PET/MRI scanner for cardiac study only for 60-90 minutes, Finally, multi-sequence, multi-planar cardiac MR images will be acquired to assess cardiac chamber size, regional wall motion abnormalities, ejection fraction, left ventricular perfusion(using gadolinium-based agent) and late gadolinium enhancement. The investigators will also conduct MRI examinations on 5 healthy volunteers to establish cardiac MRI protocol for the PET/MRI scanner. These scans will not involve any FDG administration to the healthy volunteers. These will involve cardiac MRI examinations to determine the feasibility and quality of MRI scans with the new scanner. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03923049
Study type Interventional
Source University of Alabama at Birmingham
Contact
Status Terminated
Phase N/A
Start date May 21, 2019
Completion date December 2, 2020

See also
  Status Clinical Trial Phase
Completed NCT03705884 - PET/MR Imaging In Patients With Cardiac Sarcoidosis N/A
Recruiting NCT04017936 - Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis Phase 2
Recruiting NCT06131112 - Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis
Not yet recruiting NCT05954507 - Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis N/A
Recruiting NCT04737317 - Diagnostic Criteria in Cardiac Sarcoidosis
Recruiting NCT06409585 - Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Recruiting NCT03057002 - UTSW HP [13-C] Pyruvate Injection in HCM
Completed NCT03599414 - CASPA: CArdiac Sarcoidosis in PApworth
Withdrawn NCT02812849 - Somatostatin Receptor Imaging in Cardiac Sarcoidosis
Completed NCT01729169 - Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET N/A
Completed NCT03549598 - d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis Phase 4
Recruiting NCT04758650 - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis Phase 2
Recruiting NCT04206163 - Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis N/A
Recruiting NCT05499637 - [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation Phase 2
Recruiting NCT03593759 - Cardiac Sarcoidosis Randomized Trial Phase 3
Recruiting NCT05145023 - Development and Validation of a Health-related Quality of Life Tool for Patients With Cardiac Sarcoidosis
Enrolling by invitation NCT04774549 - Inflammatory Cardiomyopathy Bern Registry
Recruiting NCT03049254 - Mayo AVC Registry and Biobank
Completed NCT03746847 - PET Imaging in Patients With Suspected Cardiac Sarcoidosis
Recruiting NCT01477359 - Cardiac Sarcoidosis Multi-Center Prospective Cohort